Yongmaotai(605208)
Search documents
永茂泰(605208) - 关于参加2025年上海辖区上市公司三季报集体业绩说明会的公告
2025-10-27 08:15
证券代码:605208 证券简称:永茂泰 公告编号:2025-072 上海永茂泰汽车科技股份有限公司(以下简称"公司")已于2025年10月28日 披露《2025年第三季度报告》,为便于广大投资者更全面深入地了解公司2025年前三 季度经营成果、财务状况,公司计划于2025年11月13日(星期四)15:00-16:30参加 2025年上海辖区上市公司三季报集体业绩说明会,就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开,公司将针对2025年前三季度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通,在信息披露允许的范围内就 投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间:2025年11月13日(星期四)15:00-16:30 会 议 召 开 地 点 : 上 海 证 券 交 易 所 上 证 路 演 中 心 ( 网 址 : https://roadshow.sseinfo.com/) 会议召开方式:上证路演中心网络互动 投资者可于2025年11月6日(星期四)至11月12日(星期三)16:00前登录上证 路 演 中 心 网 站 首 页 点 击 " ...
永茂泰(605208) - 2025年第三次临时股东会会议资料
2025-10-27 08:15
上海永茂泰汽车科技股份有限公司 2025 年第三次临时股东会 会议资料 目 录 | 2025 年第三次临时股东会会议议程 | 1 | | --- | --- | | 议案一、关于增加部分子公司担保额度的议案 | 2 | 永茂泰 2025 年第三次临时股东会会议资料 上海永茂泰汽车科技股份有限公司 2025 年第三次临时股东会会议议程 会议时间:2025 年 11 月 18 日(星期二)下午 2 时 30 分 会议地点:上海市青浦区练塘镇章练塘路 577 号永茂泰公司会议室 主要议程: 2025 年 11 月 18 日 一、主持人宣布大会开始并宣读参会人员、股东情况; 二、通过大会计票人、监票人名单; 三、审议下列议案: 1. 《关于增加部分子公司担保额度的议案》 四、股东发言提问; 七、统计表决票; 八、宣布表决结果、股东会决议; 九、公司聘请的律师发表见证意见; 十、会议主持人宣布会议结束。 1 五、主持人或相关人员回答提问; 六、对上述议案进行现场投票表决; 永茂泰 2025 年第三次临时股东会会议资料 议案一 上海永茂泰汽车科技股份有限公司 关于增加部分子公司担保额度的议案 各位股东及股东代表: 为获取 ...
永茂泰(605208) - 关于召开2025年第三次临时股东会的通知
2025-10-27 08:15
一、召开会议的基本情况 (一) 股东会类型和届次 2025年第三次临时股东会 (二) 股东会召集人:董事会 证券代码:605208 证券简称:永茂泰 公告编号:2025-071 上海永茂泰汽车科技股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: (三) 投票方式:本次股东会所采用的表决方式是现场投票和网络投票相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间:2025 年 11 月 18 日 14 点 30 分 召开地点:上海市青浦区练塘镇章练塘路 577 号永茂泰公司会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统:上海证券交易所股东会网络投票系统 网络投票起止时间:自2025 年 11 月 18 日 至2025 年 11 月 18 日 采用上海证券交易所网络投票系统,通过交易系统投票平台的投票时间为股东会召 股东会召开日期:2025年11月18日 本次股东会采用的网络投票系统:上海证券交易所股东会网络投票系统 开当日的 ...
永茂泰(605208) - 第三届董事会第十七次会议决议公告
2025-10-27 08:15
证券代码:605208 证券简称:永茂泰 公告编号:2025-069 上海永茂泰汽车科技股份有限公司 第三届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 表决结果:同意 9 票,反对 0 票,弃权 0 票。 董事会会议召开情况 上海永茂泰汽车科技股份有限公司(以下简称"公司")第三届董事会第十 七次会议于2025年10月27日在上海市青浦区练塘镇章练塘路577号永茂泰公司会 议室以现场结合通讯方式召开,会议通知和材料于2025年10月22日以电子邮件发 送全体董事和高级管理人员。会议由董事长徐宏召集并主持,应出席董事9人, 实际出席董事9人,全体高级管理人员列席会议。会议的召集和召开程序符合《公 司法》和《公司章程》的规定,会议合法有效。 董事会会议审议情况 一、审议通过《2025 年第三季度报告》。 详见 2025 年 10 月 28 日公司在《中国证券报》《上海证券报》《证券时报》 《证券日报》和上海证券交易所网站 www.sse.com.cn 披露的《2025 年第三季度 报告》。 公司 2 ...
永茂泰(605208) - 2025 Q3 - 季度财报
2025-10-27 08:10
Financial Performance - The company's operating revenue for the third quarter reached ¥1,655,077,601.36, representing a year-on-year increase of 59.65%[3] - The net profit attributable to shareholders was ¥30,405,617.67, showing a significant increase of 6319.92% compared to the same period last year[3] - The total profit for the year-to-date period was ¥48,677,720.39, reflecting a growth of 51.97% year-on-year[3] - The basic earnings per share for the third quarter was ¥0.09, an increase of 4400.00% compared to the same period last year[3] - The net profit for the first three quarters of 2025 reached CNY 51,373,155.72, an increase from CNY 35,946,551.75 in the same period of 2024, representing a growth of approximately 43%[19] - The total profit for the first three quarters of 2025 was CNY 48,677,720.39, up from CNY 32,031,147.22 in 2024, representing a growth of approximately 52%[19] - The total revenue from operating activities for the first three quarters of 2025 was CNY 4,665,919,774.41, compared to CNY 3,570,138,640.99 in 2024, indicating a year-over-year increase of about 30.6%[22] - The basic and diluted earnings per share for the current period were both CNY 0.15, up from CNY 0.11 in the previous year, reflecting a growth of approximately 36.4%[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,709,079,869.23, up 17.81% from the end of the previous year[4] - The total assets as of September 30, 2025, were RMB 4,709,079,869.23, up from RMB 3,997,236,084.29 at the end of 2024, indicating an increase of about 17.8%[16] - Total liabilities as of September 30, 2025, reached RMB 2,534,804,423.44, compared to RMB 1,896,788,658.32 at the end of 2024, reflecting an increase of approximately 33.7%[15] - The company's total equity as of September 30, 2025, was RMB 2,174,275,445.79, an increase from RMB 2,100,447,425.97 at the end of 2024, representing a growth of about 3.5%[16] - The equity attributable to shareholders increased by 3.46% to ¥2,173,077,504.61 compared to the end of the previous year[4] Cash Flow - The company reported a net cash flow from operating activities of -¥252,598,085.60 for the year-to-date period, indicating a decrease in cash flow[3] - The net cash flow from operating activities for the first three quarters of 2025 was negative at CNY -252,598,085.60, worsening from CNY -58,925,648.23 in 2024[22] - The cash and cash equivalents at the end of the period increased to CNY 167,059,171.24, compared to CNY 65,882,591.80 at the end of the previous year, marking a significant improvement[23] - Cash and cash equivalents as of September 30, 2025, were RMB 167,061,951.66, a substantial increase from RMB 50,651,388.31 at the end of 2024[13] - The investment activities generated a net cash outflow of CNY -189,112,260.15, slightly improved from CNY -204,133,509.41 in the same period last year[23] - The financing activities produced a net cash inflow of CNY 557,205,735.33, compared to CNY 220,693,667.86 in the previous year, indicating a substantial increase[23] Operational Focus - The company is focusing on expanding its customer base and increasing sales volume, which contributed to the significant growth in revenue[7] - The company has implemented an employee stock ownership plan, which impacted net profit by ¥8,185,600 for the year-to-date period[8] Expenses - Total operating costs for the first three quarters of 2025 were RMB 4,265,569,058.44, compared to RMB 2,770,396,945.45 in 2024, indicating an increase of about 54.0%[18] - Research and development expenses for the first three quarters of 2025 amounted to RMB 90,609,700.82, up from RMB 69,594,395.14 in 2024, reflecting a growth of approximately 30.2%[18] - The company reported a credit impairment loss of CNY -16,772,841.38, which increased from CNY -9,063,164.01 in the previous year, indicating a deterioration in credit quality[19] Return on Equity - The weighted average return on equity for the year-to-date period was 2.34%, an increase of 0.63 percentage points compared to the previous year[3]
73股连续5日或5日以上获主力资金净买入
Zheng Quan Shi Bao Wang· 2025-10-24 03:42
Core Insights - A total of 73 stocks in the Shanghai and Shenzhen markets have received net buying from major funds for five consecutive days or more as of October 23 [1] - The stock with the longest consecutive net buying days is Yongmaotai, which has seen net buying for 11 consecutive trading days [1] - Other notable stocks with significant net buying days include Yibin Paper, Hanghua Co., Baofeng Energy, Laofengxiang, Juxing Technology, Naxinwei, Daimei Co., and Kangwei Century [1]
82只个股连续5日或5日以上获主力资金净买入
Zheng Quan Shi Bao Wang· 2025-10-22 03:42
Core Viewpoint - As of October 21, a total of 82 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Jianyou Co., which has seen net buying for 12 consecutive trading days [1] - Other notable stocks with significant net buying days include Jingwei Hengrun, Yongmaotai, Baihe Co., ST Chuangyi, Zhongwen Media, Renfu Pharmaceutical, Ruimaite, and Chenguang Co. [1]
79股连续5日或5日以上获融资净买入
Zheng Quan Shi Bao Wang· 2025-10-21 03:41
Core Insights - As of October 20, a total of 79 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] Group 1: Stocks with Longest Continuous Net Inflows - The stocks with the longest continuous net inflows are Yongmaotai, Kede CNC, and Fanwei Network, each having recorded net inflows for nine consecutive trading days [1] - Other notable stocks with significant net inflows include Mindray Medical, BOE Technology Group, Xingqi Eye Medicine, Maixinlin, Dongfang Electronics, Cangzhou Mingzhu, Zhongke Software, and Yingke Medical [1]
永茂泰携手头部人形机器人企业,剑指行业标准!“全市场唯一两百亿规模”机器人ETF(562500) 放量上行,市场活跃
Mei Ri Jing Ji Xin Wen· 2025-10-20 06:29
Group 1 - The core viewpoint of the articles highlights the active performance of the Robot ETF (562500), which rose by 1.43% and showed a clear structural differentiation among its constituent stocks, with 62 stocks rising and 11 falling [1] - The trading volume of the Robot ETF reached approximately 9.04 billion yuan, with over 900 million shares traded, indicating a vibrant market activity [1] - A strategic cooperation framework agreement was signed between Yongmaotai and a leading domestic humanoid robot company to explore collaboration in the field of embodied intelligent robot actuators and joint components, aiming to set global industry standards [1] Group 2 - Open Source Securities predicts that humanoid robots will gradually achieve industrialization from 2024, with multiple global companies increasing their investments in this sector, thereby accelerating the industrialization process [2] - The humanoid robot industry shares significant overlaps with the smart electric vehicle sector, particularly in intelligent perception and motion control, which are similar to smart driving logic [2] - The Robot ETF (562500) is the only robot-themed ETF in the market with a scale exceeding 20 billion yuan, covering various sub-sectors such as humanoid robots, industrial robots, and service robots, facilitating investors' access to the entire robot industry chain [2]
84只个股连续5日或5日以上获主力资金净买入





Zheng Quan Shi Bao Wang· 2025-10-20 04:09
Core Insights - As of October 17, a total of 84 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stocks with the longest streak of net buying are Kaisheng Technology and Jianyou Co., both of which have seen net buying for 10 consecutive trading days [1] - Other notable stocks with significant net buying days include Wuxi Zhenhua, Jintou Chengkai, Zhucheng Technology, Lianyu Co., Yongmaotai, Yan'ao Co., Aohua Endoscopy, and Kesi Technology [1]